3Kollins SH, March JS. Advances in the pharmacotherapy of attention deficit hyperactivity disorderEJ]. Biol Psychiatry, 2007,62 : 951-953.
4Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder[J]. Overview of the Evidence, 2008,115 (6):e749 -e757.
5Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action[J].Neuropsychol Rev, 2007,17 : 61-72.
6Kim Y, Shin MS, Yoo HJ, et al. Neuroeognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD[J].Hum Psychopharmacol Clin Exp, 2009,24 : 95-102.
7Cheng JYW,Chen RYL , Ko JS,et al. Efficacy and safety of atomoxetine for attention-deficit /hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis[J]. Psychopharmacology, 2007,194 : 197-209.
8Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: Advantages, disadvantages, and clinical pearls[J]. Psychopharmacology, 2007,194 : 197-209.
9Hechtman L. Long- term treatment of children and adolescents with attention deficit/hyperactivity disorder[J].Current Psychiatry Reports, 2006,8 : 398-408.
10Findling RL. Evolution of the treatment of attentiondeficit/ hyperactivity disorder in children: a review [J].Clinical Therapeutics, 2008,30(5) : 942-956.
